Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy

SIMPLE SUMMARY: Dinutuximab beta is an antibody approved for the maintenance treatment of patients with high-risk neuroblastoma. It is being investigated in combination with different established chemotherapy regimens in various clinical settings. We reviewed the clinical charts of 25 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lode, Holger N., Ladenstein, Ruth, Troschke-Meurer, Sascha, Struppe, Linda, Siebert, Nikolai, Zumpe, Maxi, Ehlert, Karoline, Huber, Stefanie, Glogova, Evgenia, Hundsdoerfer, Patrick, Eggert, Angelika, Zaniewska-Tekieli, Anna, Balwierz, Walentyna, Wieczorek, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341209/
https://www.ncbi.nlm.nih.gov/pubmed/37444475
http://dx.doi.org/10.3390/cancers15133364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341209/
https://www.ncbi.nlm.nih.gov/pubmed/37444475
http://dx.doi.org/10.3390/cancers15133364

Ejemplares similares